Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complement System01:27

Complement System

4.1K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
4.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.1K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

10.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
10.1K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

7.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
7.5K
Antimicrobial Proteins01:23

Antimicrobial Proteins

10.0K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
10.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for?

Clinical kidney journal·2026
Same author

Humoral Response to COVID-19 Vaccines and Infection During Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy.

HemaSphere·2026
Same author

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.

JAMA·2026
Same author

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root Causes.

Kidney international reports·2026
Same journal

Targeted replacement of human γδ TCR in mice enhances antigen-specific B cell immunity.

Frontiers in immunology·2026
Same journal

Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants.

Frontiers in immunology·2026
Same journal

Enhancing immunotherapy efficacy in multiple myeloma and chronic lymphocytic leukemia: from combinatorial therapeutic approaches to gut microbiota modulation.

Frontiers in immunology·2026
Same journal

Editorial: Immune-related biomarkers in skin and breast cancer: innovations in immunological diagnostics and therapies.

Frontiers in immunology·2026
Same journal

Case report: Recurrence of anti-myeloperoxidase pauci-immune crescentic glomerulonephritis in a kidney transplant recipient; potential association with HLA antigens and seropositivity?

Frontiers in immunology·2026
Same journal

Case Report: Benralizumab combined with a steroid-sparing strategy in a case of severe eosinophilic granulomatosis with polyangiitis.

Frontiers in immunology·2026
See all related articles

Related Experiment Video

Updated: Oct 19, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway.

Jonathan Barratt1,2, Ilene Weitz3

  • 1Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.

Frontiers in Immunology
|September 27, 2021
PubMed
Summary
This summary is machine-generated.

Complement factor D is crucial for the alternative complement pathway, which amplifies immune responses. Targeting factor D offers a promising strategy for treating autoimmune diseases and inflammation caused by complement dysregulation.

Keywords:
alternative complement pathwayautoimmune diseasescomplement activationcomplement factor Dfactor Dinflammationserine protease inhibitors

More Related Videos

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.8K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.0K

Related Experiment Videos

Last Updated: Oct 19, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K
Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

30.8K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.0K

Area of Science:

  • Immunology
  • Biochemistry

Background:

  • The complement system is essential for innate immunity but its dysregulation causes autoimmune diseases.
  • The alternative complement pathway amplifies complement activation and is implicated in various pathologies.
  • Complement factor D is a serine protease and the rate-limiting enzyme in alternative pathway activation.

Purpose of the Study:

  • To review the function of complement factor D in the alternative complement pathway.
  • To discuss the role of factor D in physiological and pathological conditions.
  • To explore factor D as a therapeutic target for controlling pathological complement activation.

Main Methods:

  • Literature review of complement system function.
  • Analysis of factor D's role in alternative pathway.
  • Discussion of therapeutic implications.

Main Results:

  • Factor D is essential for the formation of the C3 convertase, a key enzyme in the alternative pathway.
  • Dysregulation of the alternative pathway, involving factor D, contributes to autoimmune diseases, inflammation, and thrombosis.
  • Factor D's central role makes it a strategic target for therapeutic intervention.

Conclusions:

  • Factor D is a critical regulator of the alternative complement pathway.
  • Targeting factor D presents a viable therapeutic strategy for diseases driven by excessive complement activation.
  • Further research into factor D inhibition could lead to novel treatments for complement-mediated disorders.